Innoviva/INVA

$15.11

1.21%
-
1D1W1MYTD1YMAX

About Innoviva

Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO ELLIPTA. The Company's products include GIAPREZA and XERAVA. GIAPREZA (angiotensin II) injection is approved by the United States Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. XERAV (eravacycline) for injection is approved by the United States FDA and Singapore Health Sciences Authority (HSA) as a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI).

Ticker

INVA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Pavel Raifeld

Employees

112

Headquarters

Burlingame, United States

Innoviva Metrics

BasicAdvanced
$945.25M
Market cap
6.67
P/E ratio
$2.24
EPS
0.57
Beta
-
Dividend rate
$945.25M
0.56994
$16.87
$11.37
675.39K
9.027
7.958
66.113
66.113
5.572
14.52%
28.97%
15.62%
6.666
3.045
1.402
2.756
6.72
-6.3%
10.35%
-2.68%
0.85%

What the Analysts think about Innoviva

Analyst Ratings

Majority rating from 1 analysts.
Hold

Price Targets

Average projection from 1 analyst.
0.73% downside
High $15.00
Low $15.00
$15.11
Current price
$15.00
Average price target

Innoviva Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
71.67% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$85.8M
27.68%
Net income
$61.5M
-25%
Profit margin
71.67%
-41.26%

Innoviva Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 230.43%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
$0.42
$0.02
$0.98
$0.76
-
Expected
$0.23
$0.26
$0.27
$0.23
$0.17
Surprise
82.61%
-92.31%
262.96%
230.43%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Innoviva stock?

Innoviva (INVA) has a market cap of $945.25M as of April 23, 2024.

What is the P/E ratio for Innoviva stock?

The price to earnings (P/E) ratio for Innoviva (INVA) stock is 6.67 as of April 23, 2024.

Does Innoviva stock pay dividends?

No, Innoviva (INVA) stock does not pay dividends to its shareholders as of April 23, 2024.

When is the next Innoviva dividend payment date?

Innoviva (INVA) stock does not pay dividends to its shareholders.

What is the beta indicator for Innoviva?

Innoviva (INVA) has a beta rating of 0.57. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Innoviva stock price target?

The target price for Innoviva (INVA) stock is $15, which is 0.73% below the current price of $15.11. This is an average based on projections from 1 analyst, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Innoviva stock

Buy or sell Innoviva stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing